Clinical TrialJun 9, 2026, 07:31 AM
BrainsWay SWIFT Deep TMS shows 80%+ MDD remission at 12 months
AI Summary
BrainsWay Ltd. announced the presentation of new 12-month durability data for its SWIFT™ Accelerated Deep TMS protocol for Major Depressive Disorder (MDD) at the Clinical TMS Society Annual Meeting. Preliminary analysis revealed that over 80% of patients treated with the SWIFT™ protocol achieved remission one year after treatment. Additionally, severe functional impairment in these patients dramatically decreased from 85% at baseline to 0% at 12 months, demonstrating sustained clinical benefits and real-world impact.
Key Highlights
- Over 80% of SWIFT™ protocol patients achieved remission through the 12-month follow-up period.
- Severe functional impairment in SWIFT™ patients decreased from 85% at baseline to 0% at 12 months.
- Less than 25% of patients had a change in medication or another TMS course within 12 months.
- Data presented is from the first multisite, randomized, controlled trial evaluating SWIFT™ protocol durability.
- The SWIFT™ protocol reduces acute phase clinic visits by 70% compared to the traditional standard protocol.
- Durable remission and functional recovery were also observed in the standard Deep TMS treatment group.
Price Impact
More from BWAY